AngioDynamics (ANGO) has surpassed earnings and revenue estimates for Q3. Further details about the company's financial performance were not provided.

AngioDynamics Inc., a medical device manufacturer, reported better than expected Q3 2025 earnings, causing a surge in its stock price. The company reported adjusted EPS of 3 cents, contrasting with the projected per-share loss of 13 cents. Furthermore, AngioDynamics reported a 9.2% YoY increase in sales to $72 million, exceeding market expectations of $70.3 million. Additionally, Med Tech's net sales rose by 22.2% to $31.3 million, driven by robust performance across all product lines.

Based on the financial report, AngioDynamics displayed strong growth in sales in the third quarter of fiscal 2025. Sales of A1 increased by 17.3% to $13.9 million, AngioVac sales rose 23.1% to $6.8 million, AlphaVac sales surged 161.4% to $3 million, and NanoKnife disposable sales increased 16.2% to $4.9 million. However, Med Device net sales remained almost the same as the previous year at $40.7 million. The gross margin improved by 290 basis points to 54.0%. The company reversed a loss of $3.6 million in the third quarter of fiscal 2024 to an adjusted EBITDA of $1.3 million in the third quarter of fiscal 2025. Looking forward, the company expects to achieve its profitability targets for fiscal year 2026 due to improved operating leverage and a strong balance sheet, which will allow it to invest in high impact initiatives. In terms of guidance, AngioDynamics anticipates fiscal-year 2025 net sales to be somewhere between $285 million and $288 million.

The article is about three stocks that are being heavily bought by insiders in October. The companies are Eton Pharmaceuticals, AngioDynamics, and Tile Shop Holdings. The significant purchases made by insiders indicate their confidence in the future prospects of these companies.

As a financial analyst, you may be interested in the details of the financial results announced by AngioDynamics, Inc. for the fiscal third quarter ended February 28, 2025. However, the actual financial figures or performance indicators are not included in this given excerpt. This information is likely to be found in the attached Exhibit 99.1, which is not provided here. The excerpt does note that the information is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to liabilities under that section. It also won't be incorporated by reference into any filing under the Securities Act of 1933, unless explicitly referenced in such a filing.

1) Brief Summary: The company's shares have shown positive performance over the past month and quarter, with monthly performance at 17.32% and quarterly performance at 21.99%. However, the company has a negative return on equity (-76.44%) and return on investment (-118.40%). Insider trading shows that the SVP of Quality and Regulatory sold 4060 shares. The company also saw a decrease in sales year over year (-13.06%) and quarter over quarter (-7.88%). The company's financial health looks risky with negative net income and decreasing total assets and total equity. 2) MARKET_SCORE: Given the company's negative return on investment and equity, along with decreasing sales, there is a 45% likelihood of an upward move. MARKET_SCORE: 45

3) PRICE_TARGET: Considering the company's current performance and financial health, the price target is estimated to be 5% higher than the latest close price. Thus, PRICE_TARGET: $11.60

4) AI_RPT_HEADLINE: "Despite Positive Share Performance, Company's Financial Health Raises Concerns"

As a financial analyst, I would choose -> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes. This comprehensive data would offer a more thorough understanding of a company's financial health, risk factors, and recent changes in their business operations. This can also provide insights into future performance and potential risks, which could significantly improve the accuracy and confidence of my analysis.

====================================================== : 2025-04-02 11:33:10

# Analysis Completed Elapsed Time: 42.86 seconds